Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 272 results for nursing

  1. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

  2. Reducing demands on health and social care services:- Do preventive oral health interventions in residential and nursing care homes reduce demands on other health and social care services?

    care services:- Do preventive oral health interventions in residential and nursing care homes reduce demands on other health and social...

  3. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

  4. Oral health in care homes (QS151)

    This quality standard covers oral health, including dental health and daily mouth care, for adults in care homes (with and without nursing provision). It describes high-quality care in priority areas for improvement.

  5. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]

    In development Reference number: GID-TA11333 Expected publication date: TBC

  6. Cerebral palsy in children and young people (QS162)

    This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.

  7. Facilitators and barriers to carrying out daily mouth care and oral health assessments for adults in care homes:- What are the facilitators and barriers to delivering daily oral care and conducting oral health assessments in residential and nursing care homes?

    daily oral care and conducting oral health assessments in residential and nursing care homes? Any explanatory notes(if applicable) Why...

  8. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date:  29 April 2027

  9. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

  10. Alcohol interventions in secondary and further education (NG135)

    This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

  11. Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

    This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.

  12. Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date:  10 March 2027

  13. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  14. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

  15. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026